



50

Technology Fast 50  
2019 Japan WINNER  
Deloitte.

GNI Group Ltd., Ranks 12  
2019 Japan Technology Fast 50,  
A Ranking of Fastest-Growing Technology Companies,  
with a 284.03% Revenue (Sales) Growth Rate

October, 18 2019 – GNI Group Ltd., (TSE Mothers listed code : 2160) announced today that it ranked 12th in the 17<sup>th</sup> Japan Technology Fast 50, with revenue (sales) growth of 284.03% based on the past three accounting periods. Japan Technology Fast 50, announced annually by Deloitte Tohmatsu Group, is a ranking of the 50 fastest-growing Japanese companies in the technology, media, and telecommunications (TMT) industries based on their revenue (sales) growth percentage based on the last three accounting periods.

( <http://www.deloitte.com/jp/fast50/2019> )

Japan Technology Fast 50 is a Japanese edition of the ranking program series of TMT industries compiled by Deloitte Touche Tohmatsu Limited (DTTL) for about 40 countries as well as for three regions: North America, EMEA and Asia-Pacific. It has been serving as a benchmark for growth potential and success for corporations in the TMT industries. Companies, both listed and unlisted, are eligible to apply for Fast 50 and the top 50 companies that have demonstrated exceptional growth in revenues (sales) based on the last three accounting periods are announced each year. Please visit <http://www.deloitte.com/jp/fast50> for further information on the program.

---

#### About GNI Group Ltd.

GNI Group Ltd. is a multinational pharmaceutical company listed on the Tokyo Stock Exchange Mothers Market, Code 2160. The Group is headquartered in Tokyo, with primary business units of pharmaceuticals and medical devices with subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information about GNI Group Ltd., please visit [www.gnipharma.com](http://www.gnipharma.com).

#### **For further inquiries**

Email: [infojapan@gnipharma.com](mailto:infojapan@gnipharma.com)

This press release contains "forward-looking" statements, including statements related to our group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause our group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. Our group does not undertake any obligation to update forward-looking statements.